One-stop facility for diabetes patients

ABU DHABI: In a regional first, the Imperial College London Diabetes Centre (ICLDC), part of the M42 group, announced it will open a dedicated one-stop facility in Madinat Zayed to provide comprehensive care for diabetes and endocrine patients.

The new tech-enabled, world-class centre in Al Dhafra will serve a critical part of Abu Dhabi’s population, providing targeted prevention and intervention for more than 6,000 diabetes sufferers in the region.

Set to open in the second half of this year, the state-of-the-art facility will bring comprehensive care closer to those in need and cut travel time by more than 75 percent. Currently, the flagship ICLDC in Abu Dhabi city serves around 9 percent of the Al Dhafra population of sufferers. The new facility in Madinat Zayed will provide greater access to sufferers across the Al Dhafra region including residents in Liwa, Mirfa, Gayathi, Ruwais, and Tarif.

In addition to providing clinical care, ICLDC will continue to promote preventive solutions for Type 2 diabetes, with an extensive community outreach programme including workshops, health screenings, and educational programmes for schools and organisations, as well as promoting an active lifestyle and healthy eating.

Hasan Jasem Al Nowais, Managing Director, and Group Chief Executive Officer, M42, said, “M42 is commited to providing world-class preventive and personalised health solutions that enable individuals to put their health back in their own hands. As a leader in diabetes and endocrine management and prevention, the Imperial College London Diabetes Centre is positively impacting lives across the UAE. Expanding our one-stop services to Al Dhafra presents an opportunity to serve a much greater number of UAE residents with an innovative model that provides premium, techenabled health solutions that result in tangible positive clinical outcomes.”

With a proven track record of nearly two decades, ICLDC’S model for diabetes prevention and management has significantly reduced Hba1c values in patients across the UAE.

ICLDC has played a key role in revolutionising population health in the UAE over the past twenty years. ICLDC’S efforts have led to a notable decrease in Hba1c levels, dropping from an average of 9.5 percent to an impressive 7.2 percent among its patients. A remarkable 57 percent of ICLDC’S patients now have Hba1c results below 7 percent, surpassing the international benchmark of 38 percent. These exceptional outcomes demonstrate the expertise and commitment of the team of over 65 consultants in diabetes and endocrine care across ICLDC’S facilities.